Loading...
GALD logo

Galderma Group AGSWX:GALD Rapporto sulle azioni

Cap. di mercato CHF 41.0b
Prezzo delle azioni
n/a
1Y36.3%
7D-1.1%
1D0.5%
Valore del portafoglio
​
Vista

Galderma Group AG

Report azionario SWX:GALD

Capitalizzazione di mercato: CHF 41.0b

Galderma Group (GALD) Panoramica del titolo

Galderma Group AG opera come azienda dermatologica a livello mondiale. Maggiori dettagli

GALD analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura4/6
Prestazioni passate5/6
Salute finanziaria4/6
Dividendi0/6

Premi

Negoziato a 41.1% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 24.3% all'anno

Gli utili sono cresciuti del 165.4% nell'ultimo anno

Analisi del rischio

Non sono stati rilevati rischi per GALD dai nostri controlli di rischio.

GALD Community Fair Values

Create Narrative

See what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Concorrenti di Galderma Group AG

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Galderma Group
Prezzi storici delle azioni
Prezzo attuale dell'azioneCHF 174.95
Massimo di 52 settimaneCHF 188.25
Minimo di 52 settimaneCHF 125.10
Beta-0.097
Variazione di 1 mese-2.56%
Variazione a 3 mesi2.34%
Variazione di 1 anno36.25%
Variazione a 3 annin/a
Variazione a 5 annin/a
Variazione dall'IPO173.36%

Notizie e aggiornamenti recenti

Aggiornamento narrativa • Jul 30

GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction

Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.
Aggiornamento narrativa • Jul 16

GALD: FDA Manufacturing Setbacks And Rich P/E Will Likely Cap Future Upside

Galderma Group's analyst price target is updated to CHF 131.68 from CHF 125.65 as analysts factor in revised fair value assumptions, including adjusted revenue growth, profit margin, and future P/E inputs, alongside recent Street target increases to as high as CHF 175. Analyst Commentary Recent Street research on Galderma Group points to a mixed tone.
Aggiornamento narrativa • Jul 01

GALD: Higher CHF Sentiment Will Test Acne Franchise Concentration Risk

Analysts have raised the Galderma Group fair value estimate by about CHF 5 to CHF 188 per share, citing updated Street research with higher CHF price targets from several major banks as support for the revised view. Analyst Commentary Recent Street research on Galderma Group has centered on a series of upward price target revisions in CHF terms, which analysts link to their reassessment of the company’s execution and potential growth options.

Recent updates

Aggiornamento narrativa • Jul 30

GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction

Galderma Group's analyst price target has moved higher toward a CHF 200 to CHF 210 range, with analysts pointing to updated expectations for Nemluvio and injectable aesthetics, alongside adjustments to revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Galderma Group highlights a clear shift toward more optimistic views, with several bullish analysts lifting price targets into the CHF 175 to CHF 210 range.
Aggiornamento narrativa • Jul 16

GALD: FDA Manufacturing Setbacks And Rich P/E Will Likely Cap Future Upside

Galderma Group's analyst price target is updated to CHF 131.68 from CHF 125.65 as analysts factor in revised fair value assumptions, including adjusted revenue growth, profit margin, and future P/E inputs, alongside recent Street target increases to as high as CHF 175. Analyst Commentary Recent Street research on Galderma Group points to a mixed tone.
Aggiornamento narrativa • Jul 01

GALD: Higher CHF Sentiment Will Test Acne Franchise Concentration Risk

Analysts have raised the Galderma Group fair value estimate by about CHF 5 to CHF 188 per share, citing updated Street research with higher CHF price targets from several major banks as support for the revised view. Analyst Commentary Recent Street research on Galderma Group has centered on a series of upward price target revisions in CHF terms, which analysts link to their reassessment of the company’s execution and potential growth options.
Aggiornamento narrativa • Jun 17

GALD: Rising Execution Bar And Rich P/E Will Likely Cap Future Share Upside

Analysts have raised the Galderma Group price target by CHF 5 to CHF 125.65, citing updated assumptions on fair value, revenue growth, profit margins and forward P/E that are consistent with a recent series of target increases from major banks. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets, framed around updated assumptions for earnings quality, revenue mix and P/E levels.
Aggiornamento narrativa • Jun 03

GALD: Rising Optimism Will Meet Acne Franchise Concentration Risk

Analysts have lifted the Galderma Group price target by about CHF 1 to roughly CHF 183.50, reflecting updated views on fair value, slightly adjusted revenue growth and profit margin assumptions, and continued supportive research commentary across several firms. Analyst Commentary Recent research has focused on how Galderma can execute on its growth plans while justifying higher valuation ranges, with several firms adjusting price targets and ratings in quick succession.
Aggiornamento narrativa • May 13

GALD: Rising Optimism Will Meet Pediatric Skin Franchise Concentration Risk

Analysts have nudged their average price target for Galderma higher by around CHF 5 to reflect updated assumptions for revenue growth, profit margins and longer term P/E expectations, following a series of recent target increases from firms such as Morgan Stanley, Citi, RBC Capital, Berenberg, H.C. Wainwright and Barclays. Analyst Commentary Recent research on Galderma Group has been active, with several firms updating their views and price targets.
Aggiornamento narrativa • Apr 28

GALD: Higher Fair Value View Will Support Future Re Rating Conviction

Analysts have increased the Galderma Group fair value estimate by about CHF 48, from roughly CHF 192 to around CHF 240. They cite recent price target increases across several firms, along with support from product driven growth assumptions and a higher future P/E multiple.
Aggiornamento narrativa • Apr 14

GALD: Elevated Expectations For Dermatology Franchise Will Likely Cap Future Share Upside

Analysts have raised the Galderma Group price target by CHF 7 to reflect updated expectations for revenue growth, profit margin and future P/E, supported by a series of recent CHF-based target increases from several research houses. Analyst Commentary Recent research updates show a cluster of higher CHF based price targets for Galderma Group, with several firms revising their assumptions around growth, margins and P/E multiples.
Aggiornamento narrativa • Mar 31

GALD: Rising Optimism Will Meet Pediatric Skin Franchise Execution Risk

The updated analyst price target for Galderma Group moves higher to reflect Street research that cites support from products like Nemluvio, tighter profit margin assumptions, a slightly adjusted discount rate, and a modestly lower future P/E expectation across recent CHF 155 to CHF 260 target revisions. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into a CHF 155 to CHF 260 range, which signals higher conviction in Galderma Group's valuation support at current levels.
Aggiornamento narrativa • Mar 17

GALD: High Expectations For Key Therapies Will Likely Restrain Future Share Returns

Narrative Update on Galderma Group The updated analyst price target for Galderma Group has moved higher in the latest model, aligning with recent Street target increases to CHF 155, CHF 200 and CHF 260, as analysts highlight support from products such as Nemluvio and adjustments to growth and margin assumptions. Analyst Commentary Recent Street research on Galderma Group points to a cluster of higher price targets in the CHF 155 to CHF 260 range, with different attitudes on how much upside may be left.
Aggiornamento narrativa • Mar 03

GALD: Elevated Growth Assumptions Will Likely Pressure Shares Despite Raised Outlook

Analysts have raised their Galderma Group price target to CHF 195 from CHF 155, reflecting updated assumptions for revenue growth, profit margins, discount rate, and future P/E that modestly reduce estimated fair value to CHF 110.71 from CHF 111.24. Analyst Commentary The latest price target move to CHF 195 sits well above the estimated fair value of CHF 110.71, which signals that some analysts are embedding optimistic assumptions on growth and profitability.
Aggiornamento narrativa • Feb 16

GALD: Higher CHF 195 Outlook Will Support Future Re Rating Conviction

Analysts have raised their price target on Galderma Group to CHF 195 from CHF 155, reflecting updated views on revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent research points to a more constructive stance on Galderma Group, with bullish analysts lifting their price targets and expressing increased confidence in the company’s execution and valuation framework.
Aggiornamento narrativa • Feb 02

GALD: Higher Future P/E Assumptions Will Likely Pressure Shares Forward

Analysts have lifted their price target on Galderma Group to CHF 195 from CHF 155, citing updated assumptions that include higher fair value estimates, a slightly adjusted discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. Analyst Commentary The move to a CHF 195 price target is framed around updated valuation work, with higher assumed fair value, a revised discount rate, and adjusted revenue and margin assumptions.
Aggiornamento narrativa • Jan 19

GALD: Raised Growth Outlook And L’Oréal Stake Increase Will Support Re Rating

Analysts have raised their blended price target range for Galderma Group to approximately CHF 195 to CHF 200 from about CHF 140 to CHF 165, citing updated fair value estimates, revised assumptions for revenue growth and profit margins, as well as a higher projected P/E multiple. Analyst Commentary Recent Street research points to a more constructive stance on Galderma Group, with several bullish analysts lifting their price targets into the CHF 140 to CHF 195 range.
Aggiornamento narrativa • Jan 05

GALD: Rising Market Optimism Will Meet Execution Risk And Fairly Balanced Prospects

Analysts have made a marginal trim to their fair value estimate for Galderma Group to approximately CHF 159.55 per share, even as Street price targets have moved higher into a CHF 140 to CHF 182 range. This reflects updated views on the stock's P/E assumptions and recent research from multiple banks.
Aggiornamento narrativa • Dec 14

GALD: Rising Market Optimism Will Meet Execution And Competitive Challenges Ahead

Analysts have nudged their blended price target for Galderma Group higher by approximately CHF 6, reflecting increased confidence in the companys faster than previously expected revenue growth, improving profit margins, and a slightly richer forward price-to-earnings multiple supported by a series of recent target hikes across the Street. Analyst Commentary Recent target hikes from multiple firms underscore a constructive stance on Galderma Group’s medium term outlook, with bullish analysts pointing to accelerating top line momentum and improving profitability as key drivers of upside to current valuation.
Aggiornamento narrativa • Nov 30

GALD: Upward Momentum In Pricing Will Face Competitive And Execution Risks Ahead

Galderma Group's fair value estimate has been raised from CHF 150.37 to CHF 153.80. This reflects analysts' positive outlook supported by a series of recent upward price target revisions in light of expectations of continued revenue growth and stable profitability.
Aggiornamento narrativa • Nov 16

GALD: Momentum In Product Approvals And Expansion Will Face Execution Challenges

Galderma Group’s analyst price target has been revised upward from CHF 149.91 to CHF 150.37. This reflects positive analyst sentiment, driven by higher recent target increases and confidence in the company’s growth prospects.
Aggiornamento narrativa • Oct 31

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.
Articolo di analisi • Oct 29

Is Galderma Group AG (VTX:GALD) Trading At A 40% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Galderma Group fair value estimate is CHF239 Current share...
Aggiornamento narrativa • Oct 17

Global Aesthetics And Aging Trends Will Drive Expansion

The analyst price target for Galderma Group has been raised, with new estimates increasing from CHF 140.69 to CHF 142.41. This change reflects analysts' optimism on the company's outlook amid steady growth expectations and supportive recent research updates.
Aggiornamento narrativa • Aug 27

Global Aesthetics And Aging Trends Will Drive Expansion

Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.
Articolo di analisi • Aug 24

Is Galderma Group (VTX:GALD) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
Nuova narrativa • May 12

Nemluvio Launch And Global Expansion Will Shape Therapeutic Dermatology Markets

Launch of Nemluvio and international expansion in China and India are expected to significantly boost revenue growth and market share.

Rendimenti per gli azionisti

GALDCH PharmaceuticalsCH Mercato
7D-1.1%-3.5%-0.9%
1Y36.3%34.9%17.7%

Ritorno vs Industria: GALD ha superato il Swiss Pharmaceuticals che ha restituito 34.9 % nell'ultimo anno.

Rendimento vs Mercato: GALD ha superato il mercato Swiss che ha restituito 17.7 % nell'ultimo anno.

Volatilità dei prezzi

Is GALD's price volatile compared to industry and market?
GALD volatility
GALD Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement4.0%
Market Average Movement4.1%
10% most volatile stocks in CH Market7.8%
10% least volatile stocks in CH Market2.2%

Prezzo delle azioni stabile: GALD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Swiss.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di GALD è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
19817,676Flemming Ornskovwww.galderma.com

Galderma Group AG opera come azienda dermatologica a livello mondiale. L'azienda offre un portafoglio di marchi e servizi basati sulla scienza che coprono lo spettro del mercato dermatologico, tra cui l'estetica iniettabile, la cura della pelle dermatologica e la dermatologia terapeutica. Il suo portafoglio di marchi di punta comprende Dysport/Azzalure, Alluzience, Restylane e Sculptra nell'estetica iniettabile; Cetaphil e Alastin nella cura della pelle dermatologica; Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac e Loceryl nella dermatologia terapeutica.

Galderma Group AG Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Galderma Group con la sua capitalizzazione di mercato?
GALD statistiche fondamentali
Capitalizzazione di mercatoCHF 41.04b
Utili (TTM)CHF 496.11m
Ricavi(TTM)CHF 4.24b
82.7x
Rapporto P/E
9.7x
Rapporto P/S

GALD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
GALD Conto economico (TTM)
RicaviUS$5.24b
Costo del fatturatoUS$1.63b
Profitto lordoUS$3.61b
Altre speseUS$3.00b
UtiliUS$613.00m

Ultimi utili riportati

Dec 31, 2025

Prossima data di guadagno

n/a

Utile per azione (EPS)2.61
Margine lordo68.86%
Margine di profitto netto11.70%
Rapporto debito/patrimonio netto32.0%

Come si è comportato GALD nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.2%
Rendimento attuale del dividendo
17%
Rapporto di remunerazione

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/04 01:15
Prezzo dell'azione a fine giornata2026/08/04 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Galderma Group AG è coperta da 28 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Yihan LiBarclays
James GordonBarclays
Fulvio CazzolBerenberg